

2006

XVI International AIDS Conference, August 13-18, 2006, Toronto, Canada

Burman W. The effect of episodic CD4-guided antiretroviral therapy on quality of life: results of the Quality of Life substudy of SMART. Poster. Abstract number: THPE0145.

Cohn D. Severity and types of clinical events by proximal CD4 cell counts in the SMART study. Poster. Abstract number: THPE0047.

El-Sadr W. Inferior Clinical Outcomes with Episodic CD4-guided Antiretroviral Therapy Aimed at Drug Conservation (DC) in SMART Study: Consistency of Finding in All Patient Subgroups. Oral.

Gibert CL, Shlay JC, Bartsch G3, Peng G, Wang J, Visnargarwala F, Raghavan S, Xiang Y, Farrough M, Perry HE, Grunfeld C, El-Sadr WM. Long-term changes in body composition among HIV-infected antiretroviral naïve persons randomized to PI vs. NNRTI vs. PI + NNRTI-based antiretroviral regimens: Results of the CPCRA 061 metabolic Study. Poster. Abstract number: WEPE0143.

Grund B. Predictors for the initial CD4 decline after antiretroviral treatment interruption in the SMART study. Poster.

MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Kozal MJ, van den Berg-Wolf M, Henely C, Huppler-Hullsiek K, Schmetter B, Dehlinger M. Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI vs PI vs NNRTI+PI-based Antiretroviral Regimens as Initial Therapy: Results of the CPCRA 058 FIRST Study. Oral. Abstract number: TUAB0102.

Lundgren JD. Progression of HIV-related disease or death (POD) in the randomised SMART study: why was the risk of POD greater in the CD4-guided ((re)-initiate ART at CD4 < 250 cells/ μ L) drug conservation (DC) vs the virological suppression (VS) arm ? Oral.

Shlay JC, Bartsch G, Peng G, Wang J, Gibert C, Visnargarwala F, Raghavan SS, Xiang Y, Farrough M, Perry HE, Kotler D, Grunfeld C, El-Sadr WM. Long-Term Changes in Lipids and Glucose/Insulin Levels Metabolic and Body Composition Changes Among HIV-Infected Antiretroviral Naïve Persons Randomized to PI vs. NNRTI vs. PI + NNRTI-Based Antiretroviral Regimens: Results of the CPCRA 061 Metabolic Study. Oral. Abstract number: THAB0101.

van den Berg-Wolf M, Peng G, Xiang Y, Huppler Hullsiek K, Chen L, MacArthur RD, Novak RM, Kozal M, Schmetter B, Henely C, Dehlinger M. Efficacy and Safety of Nevirapine versus efavirenz When Combined in ART Regimens in HIV Infected antiretroviral-Naïve Persons (The NNRTI Substudy of FIRST-CPCRA 058). Poster. Abstract number: THPE0104

XV International HIV Drug Resistance Workshop, June 13-17, 2006, Sitges, Spain

Kozal MJ, Huppler Hullsiek K, MacArthur RD, Peng G, Xiang Y, Baxter JD, Van den Berg-Wolf M. Initial Virologic Failure with HIV Drug Resistance and Impact of Resistance on Disease Progression and Death for Patients Beginning PI, NNRTI or PI+NNRTI Based Strategies: The FIRST Study. Oral.

NIMH/IAPAC International Conference on HIV Treatment Adherence, March 8-10, 2006, Jersey City, NJ

Mannheimer S, Thackeray L, Huppler Hullsiek K, Chesney M, Gardner E, Wu A, Telzak E, Lawrence J, Baxter J, Friedland G. A Randomized Comparison of Two Instruments for Assessing Self-Reported Antiretroviral Adherence. Oral and poster.

13th Conference on Retroviruses and Opportunistic Infections, February 5-9, 2006, Denver, CO

Lawrence J, Huppler Hullsiek K, Coakley E, Bates M, Weidler J, Lie Y, Pesano R, Thackeray L, Baxter J. Antiretroviral Phenotypic Susceptibility Score as a Predictor of Treatment Response in Persons with Multidrug-Resistant HIV-1. Poster.

Brar I, Shuter J, Wentworth D, Thomas A, Daniels E, Absalon J. Comparison of Diabetes Mellitus Prevalence and Risk Factors among HIV-Infected Antiretroviral (ART) Naïve Individuals versus Individuals in the National Health and Nutritional Examination Survey (NHANES) III Cohort. Poster.

El-Sadr W, Neaton J. The SMART Study. Oral.

2005

56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA, November 11-15, 2005

Gaglio PJ, Sterling R, Daniels E, Tedaldi, E. HBV-HIV Co-infection: Results of a Survey on Treatment Practices. Poster.

XIV International HIV Drug Resistance Workshop, Quebec City, Quebec, Canada, June 7-11, 2005

Kozal MJ, Huppler Hullsiek K, Leduc R, Novak RM, MacArthur RD, Lawrence J, Baxter J. Prevalence and Impact of Protease Codon 33 Mutations/Polymorphisms in Treatment-Naïve and Treatment-Experienced Patients Enrolling in Clinical Trials. Poster.

12th Conference on Retroviruses and Opportunistic Infections, February 22-25, 2005, Boston, MA

Lawrence L, Huppler Hullsiek K, Thackeray L, Abrams D, Mayers D, Crane L, Jones M, Saldanha J, Schmetter B, Dionne T, Pettinelli C, Baxter J, and for the 064 Study Team of the Terry Bein Community Programs for Clinical Research on AIDS. Final Results of CPCRA 064: A Randomized Trial Examining Structured Treatment Interruption (STI) for Patients Failing Therapy with Multi-Drug Resistant (MDR) HIV. Poster.

2004

16th Annual Conference of the Australasian Society for HIV Medicine, September 2-4, 2004, Canberra, Australia

Drummond F, Neuhaus J, Hoy J on behalf of the SMART Protocol Team and the SMART Study Investigators. The SMART (Strategies for Management of Anti-retroviral Therapy) Study – Adherence to Strategy. Oral.

XV International AIDS Conference, July 11-16, 2004, Bangkok, Thailand

Visnegarwala F, Mullin CM, Giordano TP, Martinez E, Stratton S, Shelburne III S, Gibert C, Carr A, El-Sadr WM. Racial Differences in Prevalence of Self Reported Changes in Body Habitus and their Association with Body Composition Measurements in a Cohort of HIV+ Patients (SMART Study, CPCRA 065). July 14, 2004; Poster; Abstract Number: WePeB5931.

Novak RM, Chen L, MacArthur RD, Baxter J, Huppler Hullsiek K, Peng G, Xiang Y, Henley C, Schmetter B, Uy J, van den Berg-Wolf, Kozal M, and the CPCRA 058 Study Team. Prevalence of Resistance Mutations in a Cohort of Treatment-naïve People with Chronic HIV infection: CPCRA 058. July 14, 2004; Poster; Abstract Number: WePeB5707.

Shlay JC, Visnegarwarla F, Bartsch G, Wang J, Peng G, El-Sadr WM, Gibert C, Kotler D, Grunfeld C, Raghavan S. Body Composition and Metabolic Changes in Antiretroviral-Naïve HIV-Infected Patients Randomized to Didanosine and Stavudine (ddI+d4T) vs Abacavir and Lamivudine (ABC+3TC). July 14, 2004; Oral; Abstract Number: ThOrB1360.

Burman W, Neuhaus J, Rietmeijer C, Douglas J, McCartin C. HIV transmission risk among patients enrolled in a large clinical trial evaluating treatment interruption. July 15, 2004; Poster, Abstract Number: ThPeD7625.

Mannheimer S, Morse M, Matts J, Andrews L, Miller C, Schmetter B, Friedland G, for the CPCRA 062 Study Team. Sustained benefit from a long-term antiretroviral (AR) adherence intervention: Results of a large randomized clinical trial. July 15, 2004; Oral; Abstract Number: LbOrB15.

XIII International HIV Drug Resistance Workshop, June 8-12, 2004, Costa Adeje, Canary Islands, Spain

Baxter JD, Leduc RE, DuChene A, Leong H, Furtado MR, Petruskene OV, and the CPCRA 046 Study Team. Prevalence of HIV-1 GAG Cleavage Site Mutations in Patients Failing Protease Inhibitors in the GART Study (CPCRA 046). Poster.

Lawrence J, Huppler Hullsiek K, Mayers D, Abrams D, Baxter J, and the CPCRA 064 Study Team. Baseline Resistance and Predictors of Virologic Response in the CPCRA 064 Study: A Randomized Trial of Structured Treatment Interruption for Patients with Multi-Drug Resistant HIV. Poster.

25th Annual Meeting, Society for Clinical Trials, May 23-26, 2004, New Orleans, Louisiana

Chen I, Xie Y, Neaton JD. Treatments for HIV Infection and Implications of Non-HIV Related Deaths on Trial Design. May 25, 2004, Oral, Session CPSIIC, Abstract Number: 51.

Leduc R, DuChene A, Baxa D, Markowitz N, Baxter J. A Series of Unfortunate Assays. Oral, Session CPSIC, May 24, 2004, Abstract Number: 16.

11th Conference on Retroviruses and Opportunistic Infections, February 8-12, 2004, San Francisco, CA

Mannheimer S, Matts J, Child C, Chesney M, Telzak E, Wu A, Friedland G. Low-grade symptoms worsen quality of life (QoL) for HIV-infected individuals in antiretroviral therapy (ART) clinical trials. Poster, Abstract Number: 754.

Kostman J, Grund B, Leduc R, Baxter J, Crane L. A randomized trial of 1 or 2 protease inhibitors in combination with a non-nucleoside reverse transcriptase inhibitor and background therapy in patients with virologic failure on an initial protease-inhibitor containing regimen (CPCRA 057). Poster, Abstract Number: 548.

Lawrence J, Huppler Hullsiek K, Abrams D, Baxter J. Changes in HIV resistance patterns during structured treatment interruption (STI): CPCRA 064. Poster, Abstract Number: 665.

Drummond F, Mullin C, Poehlman M. Predictors of low HDL in HIV+ patients: Effect of class of antiretroviral therapy and traditional risk factors (CPCRA 065). Poster, Abstract Number: 712.

2003

15th Annual Conference of the Australian Society for HIV Medicine, October 22-25, 2003, Cairns, Australia

Phipps S, Drummond F, Mullin C on behalf of the SMART Body Composition Substudy Team and Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. Australian

overview of radiology in the Body Composition Substudy over the first twelve months of the SMART Study. Poster.

2nd International AIDS Society Conference on Pathogenesis and Treatment, July 13-16, 2003, Paris, France

Lawrence J, Huppler Hullsiek K, Mayers D, Abrams D, Reisler R, Crane L, Schmetter B, Dionne T, Saldanha J, Jones M, Baxter J. Failure of structured treatment interruption (STI) to confer benefit in the setting of treatment failure: CPCRA 064 results by baseline CD4 count and phenotypic sensitivity score (PSS) subgroups. Oral, Abstract Number: 119.

Loutfy M, Walmsley S, Mullin C, Perez G, Neaton J. CD4+ cell increase to highly active antiretroviral therapy (HAART) at one year is predictive of clinical outcome despite incomplete viral suppression. Oral.

MacArthur RD, Chen L, Peng G, Novak R, van den Berg-Wolf M, Kozal M, Besch L, Yurik T, Schmetter B, Henely C, Dehlinger M. Efficacy and Safety of ABC+3TC versus ddI+d4T when Combined with a PI, NNRTI or Both in AR-Naive Persons on Their First HAART Regimen: The NRTI Substudy of the CPCRA 058 FIRST Study. Poster, Abstract Number: 555.

The American Thoracic Society - 99th International Conference, May 16-21, 2003, Seattle, WA

Gordin FM, Matts J, O'Brien R, Chaisson RE, Cohn D. Rifampin and Pyrazinamide (RZ) is not Hepatotoxic in the Treatment of Latent Tuberculosis Infection (LTBI) in HIV+ Persons. Oral, Abstract Number: 1667.

10th Conference on Retroviruses and Opportunistic Infections, February 10-13, 2003, Boston, MA

Lawrence J, Mayers D, Huppler Hullsiek K, Collins G, Abrams D, Reisler RB, Crane L, Schmetter B, Dionne T, Saldanha J, Jones M, Baxter J. CPCRA 064: A Randomized Trial Examining Structured Treatment Interruption (STI) for Patients Failing Therapy with Multi-Drug Resistant (MDR) HIV. Oral, February 12, 2003, Abstract Number: 67.

El-Sadr W, Neaton J, Neuhaus J, Gordin F. Comparison of Risk Factors for Coronary Heart Disease Among Men and Women Enrolled in the SMART Study (CPCRA 065). Poster, Abstract Number: 745.

2002

6th International Congress on Drug Therapy In HIV Infection, Glasgow, Scotland, November 17-21, 2002

Perez G, MacArthur R, Walmsley S, Baxter J, Mullin C, Neaton J, Schmetter B. A multinational randomized clinical endpoint study comparing nelfinavir and zidovudine in 775 patients for the Terry

Beirn Community Programs for Clinical Research on AIDS and the Canadian HIV trials Network. (CPCRA 042, NvR), Poster, Abstract Number: P43.

XIV International AIDS Conference, July 7-12, 2002, Barcelona, Spain

Fehmida Visnegarwala, M.D. Insulin resistance (IR) and prevalence of diabetes melitus (DM) in antiretroviral (ARV) naive patients coinfectd with hepatitis C (HCV) and HIV-1 compared to patients with HIV-1 infection alone. Oral, July 10, 2002, Abstract Number: WePeB5921.

Shlay J, El-Sadr W, Bartsch G, Mullin C, Gibert C, Visnegarwala F, Carr A, Rappoport C, Raghavan S. Development of a Simple Questionnaire to Assess Changes in Body Appearance among Antiretroviral (AR) Naïve HIV-Infected Patients (pts). Abstract Number: B11029; published on the Conference CD-ROM, an extension of the Abstract Book.

El-Sadr W. Design of a large study to evaluate two strategies for the use of antiretroviral drugs: the SMART study. Abstract Number is: B11175; published on the Conference CD-ROM, an extension of the Abstract Book.

El-Sadr W, Bartsch G, Carr A, Mullin C, Visnegarwala F, Rappoport C, Gibert C, Raghavan S. The Effect of HIV Disease and Demographic factors on Lipid Parameters in a Large Antiretroviral Naïve Cohort. Abstract Number: B11177; published on the Conference CD-ROM, an extension of the Abstract Book.

6th International Workshop on HIV Drug Resistance and Treatment Strategies, July 2-5, 2002, Seville, Spain

Lawrence J, Mayers D, Huppler Hullsiek K, Schmetter B, Abrams D, Baxter J. Simultaneous Genotypic and Phenotypic HIV Resistance Testing and Influence on Treatment Selection in the CPCRA 064 (MDR) Study. Poster, Abstract Number: B11177XIV.

9th Conference on Retroviruses and Opportunistic Infections on February 24, 2002

Reisler R, Han C, Burman W, Tedaldi E, Neaton J. Risk of Grade IV Adverse Events and Death in HIV Patients Co-infected with Hepatitis B and/or C Receiving HAART. Poster, Session 87, Abstract Number: 657-M.

Reisler R, Han C, Burman W, Tedaldi E, Neaton J. Incidence of Grade IV Clinical Events, AIDS, and Mortality in Large Multi-Center Cohort Receiving HAART. Oral, Session 7, February 25, 2002, Abstract Number: 36.

Burman W, El-Sadr W, Matts J, Hafner R, Crane L, Gordin F. Continued Low Rates of *Mycobacterium avium* complex (MAC) and Bacterial Pneumonia Despite Withdrawal of Azithromycin Prophylaxis Among Patients With CD4 Cell Rebound. Poster, Session 83, Abstract Number: 631-W.

2001

41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), December 16-19, 2001, Chicago, IL

Vazquez J, Peng G, Sobel J, Steele-Moore L, Schuman P, Holloway W. Dynamic evolution of the in-vitro antifungal susceptibility of *Candida* species recovered from HIV-infected women receiving fluconazole. Poster.

1st IAS Conference on HIV Pathogenesis and Treatment, July 8-11, 2001, Buenos Aires, Argentina

Mayers D, Merigan T, Wentworth D, Neaton J, Hoover M, Hoetelmans R, Verbiest W, Baxter J. Both Baseline Drug Resistance and Antiretroviral Drug Levels Are Associated With Short-Term Virologic Responses to Subsequent Drug Regimens in CPCRA 046 (GART). Poster. Abstract Number: 124.

MacArthur R. Baseline Characteristics of 725 HIV+ Antiretroviral Naïve Persons Enrolled in a Multicenter Antiretroviral Strategy Trial. Poster Abstract Number: 295.

Tedaldi E, Huppler Hullsiek K, Malvestutto C, Arduino R, Fisher E, Gaglio P, Jenny-Avital E, McGowan J, Perez G. Prevalence and Characteristics of HCV Coinfection in a Community Based HIV Clinical Trials Group. Poster, Abstract Number: 545.

Kostman J, Luskin-Hawk R, Wentworth D, Bartsch G, Malvestutto C, Abrams D. Characteristics of Patients Who Choose to Remain Antiretroviral-Naïve and Those Who Begin Antiretroviral Therapy. Poster. Abstract Number: 294.

Friedland GH, Mannheimer S, Mats J, Child C, Telzak E, Chesney M. Duration of Antiretroviral Adherence Predicts Biologic Outcomes in Clinical Trials. Oral, Abstract Number: 33.

5th International Workshop on HIV Drug Resistance and Treatment Strategies, June 4-8, 2001, Scottsdale, AZ

Hoover M, Mayers D, Wentworth D, Neaton J, Hertogs K, Verbiest W. Phenotypic and Genotypic Resistance in Patients With Virologic Failure During Salvage Therapy – 12 Week Outcome Data from the GART Study (CPCRA 046). Poster, Abstract Number: 105.

Mayers D, Merigan T, Wentworth D, Neaton J, Hoover M, Hoetelmans R, Piscitelli S, Verbiest, W, Baxter J. Both Drug Resistance and Antiretroviral Drug Levels are Associated with Short-Term Virologic Responses to Subsequent Drug Regimens in CPCRA 046 (GART Study). Poster, Abstract Number: 87.

22nd Annual Meeting of the Society for Clinical Trials, May 19-23, 2001

Chen L, Neaton J, Louis T. Defining Multiple Events in AIDS Clinical Trials. Poster, Abstract Number: P26.

2nd Clinical Pharmacology Symposium, April 2-4, 2001

Mayers D, Merigan T, Wentworth D, Neaton J, Hoover M, Hoetelmans R, Piscitelli S, Verbiest, W, Baxter J. Both Drug Resistance and Antiretroviral Drug Levels are Associated with Short-Term Virologic Responses to Subsequent Drug Regimens in CPCRA 046 (GART Study). Poster.

8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago, IL

Mannheimer S, Friedland G, Matts J, Child C, Chesney M. CPCRA 057 and CPCRA 058 - Antiretroviral Adherence Correlates with Quality of Life. Poster, Abstract Number: 485.

Markowitz N, Bebhuk J, Denning E, Abrams D. Prediction of CD4+ Cell Response to Subcutaneous Recombinant Interleukin-2 (SC rIL-2). Poster, Abstract Number: 343.

MacArthur R, Perez G, Walmsley S, Baxter J, Neaton J, Wentworth D. CD4+ Cell Count is a Better Predictor of Disease Progression than HIV RNA Level in Persons with Advanced HIV Infection on Highly Active Antiretroviral Therapy. Poster, Abstract Number: 203.

2000

40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 18, 2000, Toronto, Canada

Abrams D, Bebhuk J, Denning E, Markowitz N. IL-2 Therapy Produces No Change in HIV RNA After One Year. Oral.

XIII International AIDS Conference, July 10, 2000, Durban, South Africa

Shade SB, Rappoport C, LeSueru D, Mullin C, Eberly L. Gender differences in viral load: Results from six clinical trials. Poster

Mannheimer S, Matts J, Chen L, Child C, MacArthur R, Kostman J, et al. Self-reported antiretroviral adherence levels correlate with HIV viral load and decline over time. Oral.

El-Sadr W, Bebhuk J. The effect of gender on progression of HIV disease among patients on combination antiretroviral therapy. Oral.

Raghavan S, Chen L, El-Sadr W, Grunfeld C, Peng G, Yurik T, et al. Prevalence and factors associated with fasting hypercholesterolemia, hypertriglyceridemia, and hyperglycemia in ethnically diverse antiretroviral naïve patients (CPCRA 058). Poster.

Andrews L, Friedland G, Mannheimer S, Morse E, Miller C, Brizz B, et al. A method for assessing patient readiness to begin and adhere to highly active antiretroviral therapy (HAART). Poster.

XX International Biometric Conference, July 2-7, 2000, Berkeley, CA

Eberly L, Liu J. Relation of coenrollment to AIDS clinical trials outcomes. Oral.

2nd Symposium on HIV Drug Resistance, February 26, 2000, Frankfurt, Germany

Kolberg J, Thompson M, Baxter J, Dehlinger M, Howard S, Zamroud M, et al. Low levels of pre-existing mutant virus blunts HIV-1 response to therapy. Oral and poster.

7th Conference on Retroviruses and Opportunistic Infections, January 30, 2000, San Francisco, CA

El-Sadr W, Collins G, Raghavan S, Rappoport C, Gibert C, Carr A, et al. Prevalence of metabolic complications in a large diverse cohort of HIV-infected persons. Poster.

Burman W, El-Sadr W, Grant L, Matts J, Zeh D, Gallagher B, et al. Low rates of all opportunistic infections among patients with advanced HIV disease responding to antiretroviral therapy - the CPCRA 048 cohort. Poster.

El-Sadr W, Burman W, Grant L, Matts J, Zeh D, Crane L, et al. Prophylaxis (PROPHY) for *Mycobacterium avium* complex (MAC) can be deferred among patients (pts) with a past CD4 count <50 cells/mm³ who responded to antiretroviral therapy (ART): Results of a placebo (PLC)-controlled trial (CPCRA 048). Poster.

1999

Fifth Workshop on Case Studies in Bayesian Statistics, September 24-25, 1999

Tsai C, Chaloner K. Using prior opinions to examine sample size in two clinical trials. Poster.

The Fourth International Conference on Home and Community Care for Persons Living With HIV/AIDS, December 11, 1999, Paris, France

Turner M, Roane R, Munroe D, Petrovic L, Besch CL, Gordin F. Community representatives as partners: Bridging the gap between people with AIDS (PWAs) and researchers for effective transmission of research results in the Terry Bein Community Programs for Clinical Research on AIDS (CPCRA). Poster.

The 1999 National Conference on Women and HIV/AIDS, October 9-12, 1999, Los Angeles, CA

El-Sadr W, Bebhuk J. The effect of gender on progression of HIV disease. Poster.

Society for Clinical Trials, May 2-5, 1999

Chaloner, K. A clinical trial examining acupuncture for the treatment of HIV associated pain: Results and lessons learned. Oral.

39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 27, 1999, San Francisco, CA

El-Sadr W, Mannheimer S, Grant L, Matts J. Use of PCP and MAC prophylaxis among eligible patients with and without CD4+ rebound. Poster.

El-Sadr W, Eberly L, Cohn D. Mortality associated with the occurrence of HIV-related opportunistic diseases (Ods) prior to and since HAART. Poster.

Fisher E, Cohn D, Chaloner K, Grant L, Brosgart C, El-Sadr W, et al. Effect of Adefovir Dipivoxil (ADV) on Hepatitis B (HBV) viral load (VL) in a subset of HIV+ patients (Pts) from a randomized trial of ADV in advanced HIV disease. Oral.

3rd International Workshop on Drug Resistance & Treatment Strategies, June 23-26, 1999

Baxter J, Mayers D, Wentworth D, Neaton J, Merigan T. Final results of CPCRA 046: A pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Oral.

Mayers D, Baxter J, Wentworth D, Neaton J, Merigan T. The impact of drug resistance mutations in plasma virus of patients failing on PI-containing HAART regimens on subsequent virologic response to the next HAART regimen: Results of CPCRA 046 (GART). Poster.

Third International Conference on Nutrition and HIV Infection, April 22-25, 1999, Cannes, France

Cynthia Gibert Sai Subhasree Raghavan David Wheeler Gary Collins Norma Muurahainen Mira Madans. The effect of caloric supplements on weight and body cell mass in HIV-infected individuals with CD4 <200 cells/mm³ (CPCRA 038). Poster.

Gibert C, Muurahainen N, Collins G, Williams B, Bartsch G, Wheeler D. Body composition in HIV-infected men and women in 1996-1997. Poster.

3rd International Cohorts Meeting, June 9-10, 1999, Verona, Italy

Glenn Bartsch. Methods of collection of metabolic and cardiovascular toxicities on HAART in the CPCRA. Oral.

ALA/ATS International Conference, April 23-28, 1999, San Diego, CA

El-Sadr W, Perlman DC, Nelson E, Matts J. Outcome of 6 Months Therapy for HIV-related Tuberculosis (HIV/TB). Poster.

6th Conference on Retroviruses and Opportunistic Infections, January 31-February 4, 1999, Chicago, IL

Fisher E, Brosgart C, Cohn D, Chaloner K, Pulling C, Alston B, et al. Placebo (PLC)-Controlled, Multicenter Trial of Adefovir Dipivoxil (ADV) in Patients (PT) With HIV Disease. Oral.

Fisher E, Brosgart C, Cohn D, Chaloner K, Pulling C, Schmetter B, et al. Safety of Adefovir Dipivoxil (ADV) and Incidence of Proximal Renal Tubular Disorder (PRTD) in a Placebo (PLC)-Controlled Trial in Patients (PT) With Advanced HIV Disease. Poster.

El-Sadr W, McCabe-Yurik T, Murphy R. Intolerance (INT) to Atovaquone (ATQ) and Dapsone (DAP) and the Impact of Prior Type of INT to Trimethoprim/Sulfamethoxazole (TMS). Poster.

Brosgart C, Fisher E, Pulling C, Chaloner K, Cohn D, El-Sadr W, et al. Prevalence of Asymptomatic CMV Retinitis (CMVR) in AIDS Patients. Poster.

Gordin F, Matts J, Miller C, Chaisson R, Garcia M, O'Brien R. Risk Factors for Developing Active Tuberculosis (TB) Among HIV-infected, PPD-Positive (+) Patients (Pts). Poster.

Baxter J, Mayers DL, Wentworth DN, Neaton JD, Merigan TC. A Pilot Study of the Short-term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (GART) in Patients Failing Antiretroviral Therapy. Oral.

1998

36th Annual Meeting, Infectious Diseases Society of America (IDSA), November 12, 1998, Denver, CO

Vazquez J, Sobel J, Peng G, Schuman P, Steele-Moore L, Holloway W, et al. Evolution of vaginal *Candida* species recovered from HIV-infected women receiving Fluconazole prophylaxis: The emergence of *Candida Glabrata*? Poster.

12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998

Gibert C, Wheeler D, Collins G, Muurahainen N, Alston B, Madans M, et al. The effect of caloric supplements on weight in HIV-infected individuals with CD4 <200 cells/mm³ (CPCRA 038). Poster.

Raghavan SS, Collins G, Bartsch G, Elion R, Mannheimer S, Wheeler D, et al. Micronutrient intake among HIV-infected men & women participating in a CPCRA national trial during 1996-97. Published abstract.

Raghavan SS, Grant L, Bartsch G, Thompson M, Williams B, Mateo N, et al. Change in log₁₀ HIV RNA & protease inhibitor use associated with weight change in HIV+ men in a CPCRA clinical trial. Poster.

Williams B, Collins G, Muurahainen N, Bartsch G, Gibert C, Raghavan SS, et al. Protein intake is associated with body cell mass in weight-stable HIV+ men with CD4 <200/mm³. Poster.

Gibert C, Muurahainen N, Collins G, Williams B, Raghavan SS, Bartsch G, et al. Body composition in HIV-infected men and women in 1996-1997 (CPCRA 038). Poster.

Caldwell P, Murphy R, Chan C, Yurik T, Scoot J, El-Sadr W. Atovaquone suspension (ATQ) for prophylaxis of *Pneumocystis carinii* pneumonia (PCP): Effects of baseline prophylaxis on safety and efficacy. Poster.

Muurahainen N. Body cell mass (BCM) in HIV-infected (HIV+) males in 1996-1997. Poster.

Chaisson R, Gordin F, Matts J, Miller C, Garcia L, Hafner R, et al. A randomized trial of rifampin/pyrazinamide for 2 months vs. INH for 12 months in HIV+, tuberculin+ adults (CPCRA 004/ACTG 177/CDC/PAHO). Oral presentation and poster.

Brosgart C, Pulling C, Chaloner K, Fisher E, Coakley D, Diggins M, et al. Serum carnitine levels in AIDS patients with advanced HIV disease from the CPCRA 039 trial. Published abstract.

2nd International Workshop on Drug Resistance & Treatment Strategies, June 26, 1998, Italy

Baxter J, Mayers D, Hoover M, Winters M, Weislow O, Neaton J, et al. Prevalence and associations of the G73S mutation in patients failing protease inhibitor therapy in CPCRA 046. Poster.

ACSM 45th Meeting, June 3-6, 1998

Myers M, Walker A, Collins G, Bartsch G, Launer C, Williams B. Muscle building activity versus physical activity questionnaire as a predictor of body composition. Poster.

ALA/ATS International Conference, April 24-29, 1998, Chicago, IL

El-Sadr W, Perlman D, Matts J, Nelson E, Cohn D, Salomon N, et al. Intermittent short course therapy for the treatment of HIV-related pulmonary tuberculosis: a prospective randomized trial in the US (CPCRA 019/ACTG 222). Poster.

El-Sadr, Luskin-Hawk R, Yurik T, Pulling C, Hafner R, et al. Daily Trimethoprim-Sulfamethoxazole (TMS) is preferred choice for the prevention of *P. carinii* pneumonia. Poster

5th Conference on Retroviruses and Opportunistic Infections, February 2-5, 1998

Mayers D, Neaton J, Perez G, Baxter J, MacArthur R, Markowitz N, et al. Prior saquinavir therapy leads to a modest decrease in subsequent responses to drug regimens containing indinavir or ritonavir. Poster.

Gordin F, Chaisson R, Matts J, Miller C, Garcia L, Hafner R, et al. A randomized trial of 2 months of rifampin (RIF) and pyrazinamide (PZA) versus 12 months of isoniazid (INH) for the prevention of tuberculosis (TB) in HIV-positive(+), PPD+ patients (pts). Poster.

Shlay J, Chaloner K, Max M, Flaws B, Reichelderfer P, Wentworth D, et al. A randomized, placebo-controlled trial of a standardized acupuncture regimen or amitriptyline for pain caused by HIV-associated peripheral neuropathy. Poster.

Muurahainen N, Collins G, Wheeler D, Bartsch G, Gibert C. Nutritional status and intake of HIV-infected men in 1996-1997. Poster.

El-Sadr W, Yurik T, Luskin-Hawk R, Murphy R, Hafner R, Neaton J, et al. Increased risk of *P. carinii* pneumonia but not death or other AIDS events among trimethoprim-sulfamethoxazole intolerant patients. Poster.

Murphy R, El-Sadr W, Cheung T, Luskin-Hawk R, Yurik T, Neaton J. Impact of protease inhibitor containing regimens on the risk of developing opportunistic infections and mortality in the CPCRA 034/ACTG 277 study.

El-Sadr W, Yurik T, Luskin-Hawk R, Hafner R. Pattern and timing of adverse events after initiation of different doses of trimethoprim-sulfamethoxazole (TMS) prophylaxis for *P. carinii* pneumonia. Poster.

Brosgart C, Pulling C, Chaloner K, Fisher E, Coakley D, Verheggen R, et al. Prevalence of asymptomatic CMV retinitis in AIDS patients. Poster.

1997

37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 30, 1997, Toronto, Canada

El-Sadr W, Luskin-Hawk R, Pulling C, Yurik T, Hafner R. Daily versus Thrice Weekly Trimethoprim-Sulfamethoxazole (TMP/SMX) in the Prevention of *P. carinii* Pneumonia (PCP) (CPCRA 006). Poster.

Ferrigno L, Miller C, Bartsch G, Rukeyser J, Torres R. Survival and Progression of Disease in HIV-Infected (HIV+) Individuals in Interventional Treatment Studies as Compared to an Observational Cohort. Poster.

35th Annual Meeting of the Infectious Diseases Society of America (IDSA), September 15, 1997

El-Sadr W, Murphy R, Luskin-Hawk R, Yurik T, Hafner R. Atovaquone (ATV) versus Dapsone (DAP) in the Prevention of *P. carinii* Pneumonia (PCP) in Patients Intolerant to Trimethoprim and/or Sulfamethoxazole (TMP/SMX) CPCRA 034/ACTG 277. Oral.

Baxter J, Thompson M, MacArthur R, Markowitz N, Mayers D, LiVolsi M, et al. Viral Load and Risk of Specific Opportunistic Infections in Patients with CD4 Counts <300 cells/mm³ Enrolled in CPCRA 036. Poster.

Thompson M, Perez G, Neaton J, Howard S, Baxter J, Dehlinger M, et al. Prognostic Value of Plasma HIV RNA and CD4+ Count for Clinical Endpoints in CPCRA 036. Poster.

2nd Joint Meeting - Society for Clinical Trials and International Society for Clinical Biostatistics, July 6, 1997, Boston, MA

DuChene A, Collins G, Walker J, Child C, DePew S. Quality Control Reporting for Multicenter Trials - A Report from the CPCRA. Poster.

Child C, DePew S, Collins G. Retrospective Descriptive Study of Timeliness of Clinical Events Reporting in a National HIV Community-Based Clinical Trials Network. Oral.

ALA/ATS International Conference, May 19, 1997, San Francisco, CA

Gordin F, Matts J, Miller C, Brown Jr L, El-Sadr W. Isoniazid (INH) is Not Effective in Preventing Tuberculosis (TB) in Anergic, High-Risk, HIV-Infected Patients (PTS). Oral.

National Conference on Women & HIV, May 4, 1997, Pasadena, CA

El-Sadr W, Schuman P, Peng G, Capps L, Neaton J. Predictors of Mucosal Candidiasis Among HIV-Infected Women. Poster.

7th Annual Meeting of The Society for Healthcare Epidemiology of America (SHEA), April 28, 1997, St. Louis, MO

Gordin F, Zahnow K, Matts J, Hillman D, Finley E. A Prospective Study of Purified Protein Derivative (PPD) Conversion Rates Among Health-Care Workers (HCWs) Providing HIV Care - The Final Report. Poster.

2nd International Conference on Nutrition and HIV Infection, April 23, 1997, Cannes, France

Gibert C, Collins G, Muurahainen N, Raghavan SS, Wheeler D, Williams B, et al. Body Composition and Frequency of Muscle Building Activities in HIV Infected Men. Poster.

4th Conference on Retroviruses and Opportunistic Infections - January 22-26, 1997, Washington, DC

Cohn D, Fisher E, Franchino B, Peng G, Hodges JS, Chesnut J, et al. A prospective, randomized trial of four 3-drug regimens for treatment (Rx) of disseminated MAC disease in AIDS (DM): Excess Mortality associated with high-dose clarithromycin (C). Poster.

Kumi J, Collins G, Saravolatz LD. Does ethnicity influence the efficacy and toxicity of combination versus monotherapy with nucleosides in AIDS patients? Poster.

Baxter J, Neaton J, Wentworth D, Abrams DI. The use of protease inhibitors in the Community Programs for Clinical Research on AIDS (CPCRA). Poster.

Besch CL, Morse EV, Simon PM, Hodges JS, Franchino B. Preliminary results of a compliance study with CPCRA 007 combination nucleoside study (NuCombo). Poster.

Brosgart C, Hillman D, Neaton J, Abrams DI, Sherer R. Older age is an independent predictor of death and progression of HIV disease. Poster.

Telzak E, Chirgwin K, Nelson E, Matts J, Benson CA, Sepkowitz K. Predictors for multidrug-resistant tuberculosis (MDRTB) among HIV-infected patients and response to specific MDRTB drug regimens. Poster.

Abrams DI, Neaton J, Wentworth D, Kumi J, Markowitz N, Perez G, Baxter J, et al. Patterns of antiretroviral drug use over the past 6 years in patients enrolled in community-based clinical trials: The CPCRA experience. Poster.

1996

American Public Health Association (APHA), November 17, 1996, New York, NY

Klein M, Hardy M, Minniefield C, Capps L, Guity C, Fuentes L, et al. Focus on Primary Care as a Strategy for Ensuring Adherence With Research Studies. Poster.

Association of Nurses in AIDS Care (ANAC), October 21, 1996, Chicago, IL

Dawson K, Chesnut J, Lanier L, Bray J. Protocol-Specific Educational Materials for Patients Participating in HIV/AIDS Clinical Research. Poster.

Infectious Diseases Society of America Annual Meeting, September 19, 1996, New Orleans, LA

El-Sadr W, Perlman D, Nelson E, Matts J. High Mortality Rate Associated With HIV-Related Tuberculosis In an Observational Study. Poster.

36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 18, 1996, New Orleans, LA

Vazquez J, Steele-Moore L, Schuman P, Peng G, Holloway W, Sobel J, et al. Antifungal Susceptibility Among Candida Species Recovered From HIV-Positive Women Receiving Fluconazole Prophylaxis. Poster.

Gordin F, Matts J, Miller C, Brown Jr LS, El-Sadr W. A Prospective, Double-blind, Placebo-Controlled Trial of Isoniazid (INH) for Prevention of Tuberculosis (TB) in Anergic HIV-Infected Patients (pts) at High Risk for TB. Oral.

Donovan R, Mayers D, Bush C, Jagodzinski L, Weislow O, Baxa D, et al. Prediction of disease progression in CPCRA 007: The role of unintegrated HIV DNA (UDNA) and HIV RNA. Poster.

Thompson MA, Howard S, Nelson E, Hodges JS, Perez G, Chernoff D, et al. Correlation and distribution of baseline plasma HIV RNA and CD4+ cell counts in the first 1,101 patients in Community Programs for Clinical Research on AIDS (CPCRA) protocol 036. Poster.

El-Sadr W, Matts J, Hillman D, Brosgart C, Neaton J. Bacterial Pneumonia: A Significant Risk Among a Subgroup of HIV-Infected Patients. Poster.

XI International Conference on AIDS, July 11, 1996, Vancouver, BC, Canada

Mayers D, Saravolatz LD, Winslow D, Jagodzinski L, Collins G, Hodges JS. Viral Burden Measurements in CPCRA 007. Oral.

Pablovich SS, Walker J, Besch CL. Reasons Patients Refuse to participate in HIV Clinical Trials: Experience at One Clinical Trials Unit. Poster.

Brosgart C, Cragi C, Hillman D, Louis T, Alston B, Fisher E, et al. Final Results From a Randomized, Placebo-Controlled Trial of the Safety and Efficacy of Oral Ganciclovir for Prophylaxis of CMV Retinal and Gastrointestinal Mucosal Disease in HIV-infected Individuals with Severe Immunosuppression. Oral.

Fuentes L, El-Sadr W, Julius S, Hardy M, Guity C, Messeri P. Development of an Active Community Advisory Board in the Minority Inner City Community of Harlem, U.S.A. Poster.

Cohn D, Benson CA, Williams P, Nevin T, Korvick J, Hafner, et al. A Prospective, Randomized, Double-Blind, Comparative Study of the Safety and Efficacy of Clarithromycin (CLA) vs. Rifabutin (RBT) vs. the Combination for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia or Disseminated MAC Disease (DMAC) in HIV-Infected Patients (Pts) With CD4 Counts 100 Cells/mm^3 . Oral.

Cohn D, Fisher E, Franchino B, Hodges JS, Chesnut J, Child C, et al. Comparison of Two Doses of Clarithromycin in a Randomized Trial of Four 3-Drug Regimens for Treatment of Disseminated Mycobacterium Avium Complex Disease in AIDS: Excess Mortality Associated with High-Dose Clarithromycin. Poster.

Wentworth D, Neaton J. Time Trends in Opportunistic Events Preceding Death in a Large Cohort of HIV-Positive Patients. Poster.

Neaton J, Hogan C, Chaloner K, Forsgren J, Hare D, Larntz K, et al. CPCRA Seminars: A Model for Involvement of Patients in Community-Based Clinical Research. Poster.

Mooney K, Lambert J, Fakhry R, Deisinger G, Sippel L, McMillen L, et al. Improved Data Quality as a Result of a Research Nurse Designed Quality Assurance Program in an Urban Setting. Poster.

Schuman P, Vazquez J, Sobel JD, Goldman A, Peng G, Capps L. A Randomized Trial Comparing Fluconazole with Placebo for Prophylaxis of Mucosal Candidiasis in Women with HIV Infection. Oral.

Wheeler D, Muurahainen N, Elion R, Launer C, Gibert C, Bartsch G. Change in Body Weight (WT) as a Predictor of Death and Opportunistic Complications (OC) in HIV by History of Prior OC. Poster.

Hogan C, Hodges JS, Mugglin A, Peterson PM, Abrams DI, Saravolatz LD. The Perils of Visit-Driven Endpoints in Antiretroviral Trials. Oral.

Fisher E, Brosgart C, Hillman D, Louis T, Craig C, El-Sadr W. Predictive Factors for Developing Cytomegalovirus Disease Among AIDS Patients in a Trial of Oral Ganciclovir Prophylaxis. Poster.

El-Sadr W, Perlman D, Matts J, Nelson E, Cohn, D, Telzak E, et al. Outcome of an Induction Regimen for the Treatment of HIV-related Tuberculosis (TB): Evaluation of the Addition of a Quinolone. Poster.

Caldwell R, Cox LE, Morse EV, Pieper M, Turner M, Vallier W, et al. HIV/AIDS Community-Based Clinical Trials Achieve Low Lost-to-Followup Rates. Poster.

Gibert C, Wheeler D, Launer C, Muurahainen N, Raghavan SS, Madans M, et al. Issues in the Design and Implementation of Large Scale Community-Based Clinical Trials in Nutrition and AIDS. Poster.

Saravolatz LD, Collins G, Hodges JS, Winslow D, Pettinelli C. A Randomized, Comparative Trial of ZDV Versus ZDV Plus ddI Versus ZDV Plus ddC in Persons With CD4 Cell Counts of $<200/\text{mm}^3$. Oral.

Cobb M, Desai J, Brown Jr LS, Zannikos P, Trapnell C, Rainey P. The Effect of Fluconazole on the Clinical Pharmacokinetics of Methadone. Poster.

17th Annual Meeting, Society for Clinical Trials, May 5, 1996

Collins G, Neaton J, Wentworth D. Observational Data Analyses Within a Clinical Trials Network: The CPCRA Cross-Study Database. Poster.

Harrison M, DuChene A. Automated Edit System From Data Entry to Site Notification. Poster.

5th European Conference on HIV Infection, January 15, 1996

Torres R, Neaton J, Wentworth D, Barr M, Abrams D, Sherer R, et al. Acyclovir and Survival in an Observational Cohort Enrolled by the Community Programs for Clinical Research on AIDS (CPCRA). Poster.

3rd Conference on Retroviruses and Opportunistic Infections, January 15, 1996

Benson C, Cohn D, Williams P. A Phase III Prospective, Randomized, Double-Blind Study of the Safety and Efficacy of Clarithromycin (CLA) vs. Rifabutin (RBT) vs. CLA-RBT for Prevention of *Mycobacterium avium* Complex (MAC) Disease in HIV Patients with CD4 Count 100 Cells/mL. Poster.

Saravolatz L, Collins G, Hodges J, Winslow D. A Randomized, Comparative Trial of ZDV versus ZDV plus ddI versus ZDV plus ddC in Persons with CD4 Cell Counts of $<200/\text{mm}^3$. Oral.

1995

Infectious Diseases Society of America, October 1, 1995

Perlman D, El-Sadr W, Nelson E, Matts J, Telzak E, Salomon, N, et al. Radiographic Presentations of HIV-Related Tuberculosis Vary by CD4+ Count. Poster.

35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17, 1995

Wheeler D, Launer C, Bartsch G, Muurahainen N, Besch CL, Abrams D, et al. Change in Body Weight (WT) as a Predictor of Opportunistic Complications (OC) in HIV. Poster.

Perlman D, El-Sadr W, Nelson E, Heifets L, Telzak E, Chirgwin K, et al. Susceptibility to Levofloxacin of Clinical *Mycobacterium tuberculosis* Isolates from Patients in a Multicenter Treatment Study of HIV-related Tuberculosis. Poster.

Gibert C, Launer C, Bartsch G, Muurahainen N, Abrams DI, Besch CL, et al. Body Weight and Percent Weight Change as Predictors of Mortality in HIV. Poster.

Brosgart C, Hillman D, Louis T, Alston B, et al. A Randomized, Placebo-Controlled Trial of the Safety and Efficacy of Oral Ganciclovir for Prophylaxis of CMV Retinal and Gastrointestinal Mucosal Disease in HIV-infected Individuals with Severe Immunosuppression. Oral.

Gordin F, Nelson E, Matts J, Cohn D, El-Sadr W, et al. The Impact of Human Immunodeficiency Virus (HIV) Infection on Drug-Resistance Tuberculosis (TB) in the United States (US). Poster.

Zahnow K, Hillman D, Matts J, Finley E, Gordin F, et al. Tuberculosis (TB) Skin Test Conversion Rates Among Health Care Workers (HCWs) Providing HIV Care. Poster.

Lancet Conference on TB, September 14, 1995, Washington, DC

Telzak E, Chirgwin K, Howard S, Matts J, Perlman D, El-Sadr W. A Prospective Study of Predictors for Multidrug-Resistant Tuberculosis (MDRTB) Among HIV-Infected Patients. Poster.

16th Annual Meeting of the Society for Clinical Trials, April 30, 1995, Seattle, WA

Myers M, Green L, Krum E, Schultz T, Svendsen K. A Data Management Tool for Tracking Clinical Endpoint Reviews. Poster.

Matts J, Dain B, Launer C. A Graphical Assessment of the Potential Impact of Losses to Followup on the Validity of Study Results. Oral.

Green L, Neaton J, Bartsch G, Capps L, Deyton LR, Friedland G, et al. A Clinical Events System with Committee Review for a Large Clinical Trials Network. Oral.

Wentworth D, El-Sadr W, Zurlinden J. A Data Collection System Designed to Facilitate Participation in Multiple Concurrent Clinical Trials. Poster.

Hodges JS, Shen W. Forecasting Enrollment Capacity in a Cooperative Clinical Trial Network. Poster.

HIV Infection in Women Conference, February 22, 1995, Washington, DC

Cargo SA, Khan D, Mandel N, Phillips R, Ragland K, Rowley CY, et al. Educational Newsletter for Patients Focusing on Women, HIV/AIDS, and Clinical Research. Poster.

El-Sadr W, Brosgart C, Wentworth D, Neaton J, et al. Characteristics of HIV Disease and its Treatment Among HIV-Infected Women From Different Racial/Ethnic Groups. Poster.

Brosgart C, Craig C, Hillman D, Louis T, Fisher E, Ramser JC. Gender Differences in HIV-Related CMV Disease Incidence. Poster.

Melnick SL, Sherer R, Hillman D, Neaton J. Rates of HIV Disease Progression (DP) and Mortality (MT) in Women and Men. Poster.

Simon PM, Morse EV, Besch CL. Barriers to Compliance Among Women Co-enrolled in a PCP Prophylaxis and Compliance Protocol. Poster.

American Association for the Advancement of Science, February 20, 1995, Atlanta, GA

Neaton J. Can it Work? Does it Work? Differing Expectations for Clinical Trials. Arguments for Pragmatic Clinical Trials for Persons with HIV. Oral.

2nd National Conference on Human Retroviruses and Related Infections, February 15, 1995, Washington, DC

Neaton J. Considerations in Specifying the Duration of Followup of Antiretroviral Trials. Oral.

Gibert C, Wentworth D. Cytomegalovirus (CMV) Disease and Mycobacterium Avium (MAC) Disease in HIV-infected Patients. Poster.

1994

APHA 122nd Annual Meeting, October 30-November 3, 1994

Brown Jr LS, Neaton J, Wentworth D, Sherer R, Besch CL. Disease Progression and Survival Among HIV-Infected Injecting Drug Users (IDUs) by Gender. Poster.

X International Conference on AIDS, August 7, 1994, Yokohama, Japan

Pamphile R, Flam R, El-Sadr, W. Tailoring HIV Care to Community Needs: The Harlem Hospital Experience. Poster.

Besch CL, Morse EV, Simon PM, Bincsik A, Cefali F, Connett J, et al. Determinants of Levels of Compliance in Patients Enrolled in a PCP Prophylaxis Protocol (Community Programs for Clinical Research on AIDS (CPCRA)): Baseline Data. Poster.

Brown Jr LS, Neaton J, Wentworth D, Sherer R, Besch CL, et al. Disease Progression and Survival Among HIV-Infected Injecting Drug Users (IDUs) By Gender. Poster.

Abrams DI, Wentworth D, Neaton J, Sherer R, Deyton LR, et al. Malignant Outcomes from a Cross-Study Analysis of Patients Participating in a Community-Based Clinical Trials Program. Poster.

Brosgart C, Craig C, Louis T, Hillman D, Costanzo L, Timpone J, et al. Design and Demographics in a Multicenter Trial of Cytomegalovirus (CMV) Prophylaxis in Advanced HIV Disease. Oral presentation.

Egger M, Wentworth D, Von Overbeck J, Sherer R, Ledergerber B, Saravolatz LD, et al. Mortality in HIV Infection in Switzerland and U.S.A. Poster.

El-Sadr W, Wentworth D, Cohn D, Gordin F, Brosgart C, Costanzo L, et al. A Strategy for the Evaluation of Multiple Prophylactic Agents for Opportunistic Infections Among HIV-Infected Patients. Oral.

Fuentes L, El-Sadr W, Capps L, Hardy M, Guity C, Caras SP. An Effective System for Tracking Challenging Populations in Community Based HIV Research. Poster.

John SL, Brown Jr LS, Neaton J, Wentworth D. Disease Progression and Survival Among HIV-Infected Injecting Drug Users (IDUs) by Enrollment in Drug Abuse. Poster.

Markowitz N, El-Sadr W, Wentworth D, Gordin F, Neaton J. Risk of PCP in a Contemporaneous Cohort of HIV+ Patients. Poster.

Saravolatz LD, Winslow D, Stein D, Dehlinger M, Collins G, Deyton LR. Design and Implementation of a Community Based Trial for the Comparison of Combination ZDV with ddC or ddI to ZDV Monotherapy. Poster.

Torres RA, Tobin JN, Vaughn A, Podhurst L, Bolden B, Raschella N. Oral Lesions in Patients with HIV Infection Enrolled in CPCRA Trials. Poster.

Sampson J, Ward T, Wentworth D, Wallace J. Effect of Concorde Study Release on Anti-Retroviral (AR) Use in Community Programs for Clinical Research on AIDS (CPCRA) Trials. Poster.

5th International Meeting on Bayesian Statistics, June 15, 1994, Alicante, Spain

Carlin B, Goldman, A. Bayesian Evaluation of CD4 Count as a Surrogate Endpoint in Patients with Advanced HIV Infection. Oral.

1994 ALA/ATS International Conference, May 22-25, 1994, Boston, MA

Gordin F, Matts J, Cohn D, Nelson E, El-Sadr W. The Impact of HIV on Tuberculosis (TB) Drug Resistance Rates in the United States. Oral.

15th Annual Meeting of the Society for Clinical Trials, May 8, 1994

Neaton J, Deyton L, Schnittman S, Durfor C, Meschino J, Green L, et al. Adverse Experience Reporting. Oral.

Brasler M, Ramser JC, Ragland K, Maiatico G. Case Study Approach in Protocol-Specific Training. Poster.

The Biometric Society Spring Meeting, April 10, 1994, Cleveland, OH

Goldman A, Bailey J. Confounding and Covariate Adjustments of Proportional Hazards Estimates of Relative Risk in AIDS Studies. Poster.

1st National Conference on Human Retroviruses and Related Infections, January 15, 1994, Washington, DC

Saravolatz L, Winslow D, Stein D, Dehlinger M, Collins G, Church T, et al. Design and Implementation of a Community Based Trial for the Comparison of Combination Zidovudine (ZDV) with DDC or ddI to ZDV Monotherapy. Poster.

1993

33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 17, 1993, New Orleans, LA

Burns D, Hillman D, Gordin F, Sherer R, Neaton J. Smoking and HIV-1 Infection: Demographic Characteristics, CD4+ Levels, and Clinical Outcomes in a Large, Community-Based Cohort. Oral.

El-Sadr, W, Wentworth D, Neaton J. Ordered Risk by CD4 for Opportunistic Infections (OIs) in HIV-Infected Patients (pts). Poster.

Irvin K, Finley E, Matts J, Nelson E, Dratter V, Gordin F. Rate of Tuberculosis (TB) Infection Among Health Care Workers (HCWs) Providing Care to HIV+ Populations. Oral.

VI Annual AIDS Update Conference, October 13, 1993, San Francisco, California

Bolden B, Brown H. Factors Influencing Participation in Clinical Trials. Poster.

VIIIth International Conference on AIDS in Africa & VIIIth African Conference on STDs, August 31, 1993

Schuman P, Goldman A, Peng G, Korvick J, Costanzo L, Kerkering T. The First 261 Enrollees in the Women's Fungal Prophylaxis Study. Poster.

Joint Statistical Meetings, August 15, 1993, San Francisco, CA

Neaton J, Wentworth D. The Design and Phase-in of a Large, Simple Trial in HIV Disease. A Unique Plan for Data Collection. Oral.

Neaton J, Wentworth D. Statistical Design Considerations For a Large, Simple Trial (LST) on Timing of Combination Nucleoside Treatment. Oral.

5th International Social Work and AIDS Conference, June 23, 1993, San Francisco, CA

Cox LE, Markowitz M, Rouff J. Community Advisory Boards: A Communication Bridge in AIDS Research. Oral.

IX International Conference on AIDS, June 7, 1993, Berlin

Bachelor L, Ackerman K, Sheridan P, Pacht C, Swanson K, Winslow D. Quantitation of HIV Plasma Viremia Using the Branched DNA Signal Amplification and P24 Antigen Assays During Combination Nucleoside Antiviral Therapy. Poster.

Loveless M, Sherer R, Crane LR, Neaton J. The Impact of Prior Oral Imidazole Therapy on HIV-Associated Cryptococcal Infection. Poster.

Church T, Horsburgh CR, Brelje T, Cohn D, Gibert C. Effects of Disseminated Mycobacterium avium Complex and Its Treatment on Survival of AIDS Patients: An Observational Study. Poster.

Neaton J, Wentworth D, Rhame F, Hogan C. Is Disease Progression the Optimal Endpoint for AIDS Clinical Trials? Oral.

Walker J, Pablovich SS, Besch CL. Successful Implementation of Standardized Tuberculosis (TB) Skin Testing and Recruitment to Related Protocols. Poster.

Brown Jr LS, Neaton J, Wentworth D, Sherer R, Besch CL. Injection Drug Users (IDUs) and Non-IDUs: Are There Differences in HIV Disease Progression and Survival? Oral.

Abrams DI, Goldman A, Launer C, Korvick J, Crane LR, Deyton LR. Results of a Randomized Open-Label Comparison Trial of ddI and ddC in HIV-Infected Patients Who Are Intolerant of or Have Failed ZDV Therapy. Oral.

Fuentes L, El-Sadr, Guity C, Quint E, Capps L. A Preliminary Assessment of the Degree of Integration of Community-Based Physicians in Clinical Trials for HIV. Oral.

Wentworth D, Neaton J, Luskin-Hawk R, Perez G, Taylor V, Deyton LR. Design and Logistical Features of a Large, Simple Trial in AIDS. Poster.

El-Sadr W, Wentworth D, Dehlinger M, Larntz K. Design and Implementation of a Community-Based Trial for Prophylaxis for P. Carinii Pneumonia (PCP). Poster.

Thompson C, Gordin F, Muth K, Daniels K, Matts J, Maiatico G. Two-Stage Tuberculin (PPD) Skin Testing in Individuals With HIV Infection. Poster.

Fifty First Annual Meeting of the United States Mexico Border Health Association (USMBHA) Pan American Health Organization (PAHO), Albuquerque, June 6-9, 1993, New Mexico

Salvador G, Bolden B, Brown H, Crespo J, Podhurst L, Tobin JN, et al. HIV+/AIDS Latinos Enrolled in Clinical Trials: A Report from Two Primary Care Community Health Centers in Newark, New Jersey. Poster.

ALA/ATS International Conference, May 16-19, 1993, San Francisco, CA

Gordin F, Thompson C, Matts J, Muth K, Korvick J, Deyton LR. The Utility of Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection. Poster.

14th Annual Meeting of the Society for Clinical Trials, May 1, 1993

Church T, Dehlinger M, Saravolatz LD, Stein D, Winslow D, Collins G. Design of a Randomized Trial of Combined Nucleoside Analog Antiretroviral Therapy in AIDS Patients. Poster.

1992

APHA 120th Annual Meeting, November 1, 1992

Rodriguez R, Melnick SL, Korvick J, Sherer R, Lackman C, Hillman D, et al. Differences in HIV/AIDS Therapy by Age and Sex: Preliminary Findings of the Observational Data Base (ODB) of the Community Programs for Clinical Research on AIDS (CPCRA). Poster.

Melnick SL, Sherer R, Hillman D, Rodriguez E, Lackman C, Capps L, et al. Gender and HIV-Related Clinical Events/Mortality: The Community Programs for Clinical Research on AIDS (CPCRA). Oral.

32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 1, 1992

Sacks L, Neaton J, Sherer R, Deyton LR, Korvick J, Rhame F, et al. Very Low CD4 Counts Are They Meaningful? Poster.

VIII International Conference on AIDS, July 19, 1992, Amsterdam

Markowitz M, Cox LE, Saravolatz L. The Role of the AIDS Clinical Trial Social Worker (ACTSW) in the Community Programs for Clinical Research on AIDS (CPCRA). Poster.

Besch CL, Collins G, Morse EV, Simon PM. Cofactors Associated With Participant Compliance in Two CPCRA Trials. Poster.

Saravolatz LD, Neaton J, Sherer J, Deyton LR, Korvick J, Rhame F. Single Measurement of CD4 and Prior AIDS-Defining OIs and OMs Are Important Determinants of Death. Poster.

Macey L, El-Sadr W, Capps L, Guity C. Inclusion of Pregnant Women in Clinical Trials: A Dilemma in the AIDS Era. Poster.

Louis T, Brelje T, Cohen C, Loveless K, Sherer R. Cross-Sectional Relations Between CD4 Absolute and Percent. Poster.

Price R, Daniels E, Rhame F, Bartsch G, Deyton LR, Neaton J, et al. Progression of HIV Disease: Definitions, Criteria, and Data Processing Systems of CPCRA. Poster.

Abrams DI, Goldman A, Launer C, Crane LR, Korvick J, Deyton, LR, et al. Design and Characteristics of a Randomized Open Label Trial of dideoxyinosine (ddI) Versus dideoxycytidine (ddC) in HIV-Infected Patients: A Multi-Center Study of the Community Programs for Clinical Research on AIDS (CPCRA). Poster.

Sherer R, Melnick SL, Hillman D, Rodriguez E, Lackman C, Capps L, et al. Gender, HIV-Related Clinical Events, and Mortality: Preliminary Observational Data from the Community Programs for Clinical Research on AIDS (CPCRA). Oral.

Luskin-Hawk R, Sherer R, Brelje T, Lackman C, Louis T. Predictive Value of HIV-Related Non-AIDS Clinical Conditions Based on CPCRA Observational Data. Poster.

Lackman, C. Successful Partnerships for Providing HIV Treatments to AIDS Patients: Community-Based Clinical Research. Poster.

Brown Jr LS, Lackman C, Sherer R, Wentworth D, Neaton J. Ethnicity and Survival: Preliminary Findings of the Community Programs for Clinical Research on AIDS (CPCRA). Poster.

Fourth International Social Work Conference, July 1992

Cox LE, Markowitz M. Community Advisory Boards: Missions in AIDS Research. Poster.

13th Annual Meeting of the Society for Clinical Trials, May 1, 1992

Maiatico G, Daniels K, Hogan C, Ragland K, Serra B, Deyton LR. Strategies for Educating and Training Clinicians To Conduct Community-Based Research: A Report from the Community Programs for Clinical Research on AIDS. Poster.

Carlyn M, Abrams DI, Sanville J, Neaton J, Korvick J, Deyton LR. Organization, Goals, and Logistical Challenges of the Community Programs for Clinical Research on AIDS. Oral.

Hedderman M, Jorgenson S, Deyton LR. Performance Evaluation of Centers Participating in a Multicenter Clinical Trials Group: A Model Developed for the Community Programs for Clinical Research on AIDS (CPCRA). Poster.

Matts J, Daniels K, Gordin F, Korvick J, Deyton LR. Simplifying Large Trials: An Example from the Community Programs for Clinical Research on AIDS. Poster.

Neaton J. Relative Efficiency of Taking Research to the Patient Versus the Patient to Research. Oral.

Rolnick S, Hogan C, Pogue R, Besch CL. The Use of Computer-Assisted Instruction (CAI) For Protocol Training. Poster.

American Thoracic Society/American Lung Association, May 1992

Gordin F, Daniels K, Sherer R, Brown Jr LS, Markowitz N, Quint E, et al. Prevalence of Tuberculosis Infection in HIV-Infected Persons. Poster.

Biometric Society, March 13, 1992

Neaton J. The Challenges and Opportunities of Large, Simple, Community-based Clinical Trials. Oral.

Association for Practitioners in Infection Control, January 1992

Muth K, Thompson C, Gordin F, Korvick J, Daniels K, Matts J, et al. Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection. Poster.

1991

VII International Conference on AIDS, June 15, 1991, Florence, Italy

Hardy M, El-Sadr W, Guity C, Traynor M, Capps L, Khanyile C, et al. A Successful Recruitment Effort for Clinical Trials on AIDS Amongst Difficult To Reach HIV-Infected Populations in Harlem: The Homeless, Substance Users and Women. Poster.

Cox LE, Markowitz M. Social Workers' Contributions to AIDS Clinical Trials. Poster.

Besch CL, Simon P, Morse E, Walker J, Pablovich SS, Williams D. Barriers to Recruitment, Retention and Compliance Arising from the Unique Needs of Traditionally Underserved Patient Populations. Poster.

Macey L, Rodriguez E, Melnick SL, Carlyn M, Collins G, Deyton LR, et al. Demographic and Clinical Characteristics of Women Enrolled in the Community Programs for Clinical Research on AIDS (CPCRA). Poster.

Deyton LR, Carlyn M, Hedderman M, Maiatico G, Hoth DF, Fauci A. A National Community-Based AIDS Research Program: The Community Programs for Clinical Research on AIDS (CPCRA). Poster.

Lackman C, Sherer R, Louis T, Capps L, Brown Jr LS, Carlyn M, et al. The CPCRA Observational Data Base Project: Preliminary Clinical Findings. Poster.

Sawyer RC, Brown Jr LS, Skinner A. Drug Abuse Treatment Programs as a Setting for HIV Treatment and Research. Poster.